Abstract
Entering into its fifth decade, vitrectomy continues to be an effective and safe solution for a myriad of vitreoretinal diseases. As knowledge about vitreous and the vitreoretinal interface continues to expand, vitrectomy technology and techniques have responsively evolved. The most recent innovations have included refinements of vitreous cutter and aspiration systems, improvements in illumination source and light delivery devices, and enhancements to intraoperative visualization systems. More excitingly, there are several emerging developments on the horizon, including the integration of augmented reality technology, robotic vitreoretinal surgery, gene and stem cell-based therapies, retinal prostheses, and novel drug delivery methods. This fantastic process of evolution continues to improve the safety and efficacy of vitrectomy, as well as expand its indications. As surgical outcomes continue to improve and complications are mitigated, new indications for vitrectomy have developed. Minimal vitrectomy that involves removal of floaters or early preretinal membranes along with the posterior vitreous cortex and sparing the anterior vitreous may become the standard of care for certain indications, thereby reducing post-vitrectomy cataract development [see chapter V.B.8. Floaters and vision – current concepts and management paradigms]. With advanced imaging, such as spectral-domain OCT, we have identified new pathologies like vitreo-macular adhesion, which has been shown to play a role in diabetic retinopathy (DR) and exudative AMD. “Preventive surgery” for AMD and DR may become acceptable to arrest disease process early on. Such preemptive surgery may help to reduce blinding complications in their advanced stages. Application of pharmacologic vitreolysis before pars plana vitrectomy will encourage even more liberal use of vitrectomy for such “new indications” [see chapter VI.A. Pharmacologic vitreolysis].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971;75(4):813–20.
Recchia FM, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS. Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology. Ophthalmology. 2010;117(9):1851–7. Elsevier Inc.
Oshima Y, Wakabayashi T, Sato T, Ohji M, Tano Y. A 27-gauge instrument system for transconjunctival sutureless microincision vitrectomy surgery. Ophthalmology. 2010;117(1):93–102. Elsevier Inc.
Hubschman J-P, Bourges J-L, Tsui I, Reddy S, Yu F, Schwartz SD. Effect of cutting phases on flow rate in 20-, 23-, and 25-gauge vitreous cutters. Retina. 2009;29(9):1289–93.
Binder S, Wimpissinger B, Kellner L. Current clinical data and future (for small-gauge vitreoretinal surgery). In: Rizzo S, Patelli F, Chow DR, editors. Vitreo-retinal surgery. Berlin/Heidelberg: Springer; 2009. p. 213–22.
Magalhães O, Maia M, Maia A, Penha F, Dib E, Farah ME, et al. Fluid dynamics in three 25-gauge vitrectomy systems: principles for use in vitreoretinal surgery. Acta Ophthalmol. 2008;86(2):156–9.
Magalhães O, Maia M, Rodrigues EB, Machado L, Costa EF, Maia A, et al. Perspective on fluid and solid dynamics in different pars plana vitrectomy systems. Am J Ophthalmol. 2011;151(3):401–5.e1. Elsevier Inc.
Steel DHW, Charles S. Vitrectomy fluidics. Ophthalmologica. 2011;226 Suppl 1:27–35.
DeBoer C, Fang S, Lima LH, McCormick M, Bhadri P, Kerns R, et al. Port geometry and its influence on vitrectomy. Retina. 2008;28(8):1061–7.
Barnes AC, Deboer CM, Bhadri PR, Magalhaes Jr O, Kerns RM, Mccormick MT, et al. 25-gauge instrumentation: engineering challenges and tradeoffs. In: Rizzo S, Patelli F, Chow DR, editors. Vitreo-retinal surgery. Berlin/Heidelberg: Springer; 2009. p. 9–29.
Chen C-J, Satofuka S, Inoue M, Ishida S, Shinoda K, Tsubota K. Suprachoroidal hemorrhage caused by breakage of a 25-gauge cannula. Ophthalmic Surg Lasers Imaging. 2008;39(4):323–4.
Charles S. An engineering approach to vitreoretinal surgery. Retina. 2004;24(3):435–44.
Tolentino FI, Freeman HM. A new lens for closed pars plana vitrectomy. Arch Ophthalmol. 1979;97(11):2197–8.
Chalam KV, Shah VA. Optics of wide-angle panoramic viewing system-assisted vitreous surgery. Surv Ophthalmol. 2004;49(4):437–45.
Spitznas M. A binocular indirect ophthalmomicroscope (BIOM) for non-contact wide-angle vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 1987;225(1):13–5.
Oshima Y, Chow DR, Awh CC, Sakaguchi H, Tano Y. Novel mercury vapor illuminator combined with a 27/29-gauge chandelier light fiber for vitreous surgery. Retina. 2008;28(1):171–3.
Ohji M, Huang S, Kaiser P, Tornambe P, Gotzaridis S. Pearls from experts. In: Rizzo S, Patelli F, Chow DR, editors. Vitreo-retinal surgery. Berlin/Heidelberg: Springer; 2009. p. 223–30.
Mathias M, Ernst BJ, Pichi F, Torrazza C, Ciardella A, Oliver SCN. Thermal deformation of chandelier endoillumination probes exposed to uveal tissue and blood. Retina. 2012;32(4):773–5.
Synergetics. Illuminated infusion chandeliers [Internet]. Available from: http://synergeticsusa.com/products/standard/illumination.
Chalam KV, Shah GY, Agarwal S, Gupta SK. Illuminated curved 25-gauge vitrectomy probe for removal of subsclerotomy vitreous in vitreoretinal surgery. Indian J Ophthalmol. 2008;56(4):331–4.
Oliveira TB, Trevelin LC, Moreira FMA, Bagnato VS, Schor P, de Carvalho LAV. Development and preliminary results of a chromatic illumination system for indirect ophthalmoscopes. Arq Bras Oftalmol. 2009;72(2):146–51.
Ortiz RG, Lopez PF, Lambert HM, Sternberg P, Aaberg TM. Examination of macular vitreoretinal interface disorders with monochromatic photography. Am J Ophthalmol. 1992;113(3):243–7.
Elsner AE, Burns SA, Weiter JJ, Delori FC. Infrared imaging of sub-retinal structures in the human ocular fundus. Vision Res. 1996;36(1):191–205.
Stellaris PC. Brochure – Bausch + Lomb [Internet]. Available from: www.bausch.com/en/…/Stellaris-PC-ECP-Brochure.ashx.
Shekhar R, Dandekar O, Bhat V, Philip M, Lei P, Godinez C, et al. Live augmented reality: a new visualization method for laparoscopic surgery using continuous volumetric computed tomography. Surg Endosc. 2010;24(8):1976–85.
Nakamoto M, Ukimura O, Faber K, Gill IS. Current progress on augmented reality visualization in endoscopic surgery. Curr Opin Urol. 2012;22(2):121–6.
Chu MWA, Moore J, Peters T, Bainbridge D, McCarty D, Guiraudon GM, et al. Augmented reality image guidance improves navigation for beating heart mitral valve repair. Innovations (Phila). 2012;7(4):274–81.
Nicolau S, Soler L, Mutter D, Marescaux J. Augmented reality in laparoscopic surgical oncology. Surg Oncol. 2011;20(3):189–201. Elsevier Ltd.
Greenberg K. Vantage Surgical Systems Joins Total Immersion’s North America Partner Network, Seeks to Deploy Augmented Reality in Live Surgery [Internet]. Reuters. 2010 [cited 4 Apr 2013]. Available from: http://www.reuters.com/article/2010/11/30/idUS106815+30-Nov-2010+BW20101130.
Ehlers JP, Tao YK, Farsiu S, Maldonado R, Izatt JA, Toth CA. Integration of a spectral domain optical coherence tomography system into a surgical microscope for intraoperative imaging. Invest Ophthalmol Vis Sci. 2011;52(6):3153–9.
Rohlfing T, Denzler J, Grässl C, Russakoff DB, Maurer CR. Markerless real-time 3-D target region tracking by motion backprojection from projection images. IEEE Trans Med Imaging. 2005;24(11):1455–68.
Rush R, Sheth S, Surka S, Ho I, Gregory-Roberts J. Postoperative perfluoro-N-octane tamponade for primary retinal detachment repair. Retina. 2012;32(6):1114–20.
Santos RAV, Keegan DJ, Fuchs BS, Song BJ, Avila MP, Simpson N, et al. DFPE, partially fluorinated ether: a novel approach for experimental intravitreal tamponade. Retina. 2013;33(1):120–7.
Romano MR, Zenoni S, Arpa P, Mariotti C. Mixture of ether and silicone oil for the treatment of inferior complicated retinal detachment. Eur J Immunol. 2013;43(3):230–5.
Kralinger MT, Stolba U, Velikay M, Egger S, Binder S, Wedrich A, et al. Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study. Graefes Arch Clin Exp Ophthalmol. 2010;248(8):1193–8.
Chen H, Feng S, Liu Y, Huang Z, Sun X, Zhou L, et al. Functional evaluation of a novel vitreous substitute using polyethylene glycol sols injected into a foldable capsular vitreous body. J Biomed Mater Res A. 2013;28:1–10.
Tao Y, Tong X, Zhang Y, Lai J, Huang Y, Jiang Y-R, et al. Evaluation of an in situ chemically crosslinked hydrogel as a long-term vitreous substitute material. Acta Biomater. 2013;9(2):5022–30. Acta Materialia Inc.
Schramm C, Spitzer MS, Henke-Fahle S, Steinmetz G, Januschowski K, Heiduschka P, et al. The cross-linked biopolymer hyaluronic acid as an artificial vitreous substitute. Invest Ophthalmol Vis Sci. 2012;53(2):613–21.
Yamamoto S, Hirata A, Ishikawa S, Ohta K, Nakamura K-I, Okinami S. Feasibility of using gelatin-microbial transglutaminase complex to repair experimental retinal detachment in rabbit eyes. Graefes Arch Clin Exp Ophthalmol. 2013;3:1109–14.
Holligan DL, Gillies GT, Dailey JP. Magnetic guidance of ferrofluidic nanoparticles in an in vitro model of intraocular retinal repair. Nanotechnology. 2003;14(6):661–6.
Farid M, Steinert RF. Femtosecond laser-assisted corneal surgery. Curr Opin Ophthalmol. 2010;21(4):288–92.
Abell RG, Kerr NM, Vote BJ. Toward zero effective phacoemulsification time using femtosecond laser pretreatment. Ophthalmology. 2013;25:1–7.
Nakano T, Sugita N, Ueta T, Tamaki Y, Mitsuishi M. A parallel robot to assist vitreoretinal surgery. Int J Comput Assist Radiol Surg. 2009;4(6):517–26.
Ueta T, Yamaguchi Y, Shirakawa Y, Nakano T, Ideta R, Noda Y, et al. Robot-assisted vitreoretinal surgery: development of a prototype and feasibility studies in an animal model. Ophthalmology. 2009;116(8):1538–43, 1543.e1–2. American Academy of Ophthalmology.
Rahimy E, Wilson J, Tsao T-C, Schwartz S, Hubschman J-P. Robot-assisted intraocular surgery: development of the IRISS and feasibility studies in an animal model. Eye (Lond). 2013;27(8):972–8.
Gonenc B, Balicki MA, Handa J, Gehlbach P, Riviere CN, Taylor RH, et al. Evaluation of a micro-force sensing handheld robot for vitreoretinal surgery. Rep U S. 2012;2012:4125–30.
Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel J-A, Stanga PE, et al. Interim results from the international trial of Second Sight’s visual prosthesis. Ophthalmology. 2012;119(4):779–88.
Da Cruz L, Coley BF, Dorn J, Merlini F, Filley E, Christopher P, et al. The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol. 2013;20:1–5.
Fernandes RAB, Diniz B, Ribeiro R, Humayun M. Artificial vision through neuronal stimulation. Neurosci Lett. 2012;519(2):122–8. Elsevier Ireland Ltd.
Facts about alpha IMS retina implant [Internet]. Available from: http://retina-implant.de/en/default.aspx.
Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug Dev Ind Pharm. 2013;39(11):1599–617.
El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res. 2010;29(6):443–65. Elsevier Ltd.
González-Alvarez M, González-Alvarez I, Bermejo M. Hydrogels: an interesting strategy for smart drug delivery. Ther Deliv. 2013;4(2):157–60.
Yasukawa T, Tabata Y, Kimura H, Ogura Y. Recent advances in intraocular drug delivery systems. Recent Pat Drug Deliv Formul. 2011;5(1):1–10.
Bergeles C, Kummer MP, Kratochvil BE, Framme C, Nelson BJ. Steerable intravitreal inserts for drug delivery: in vitro and ex vivo mobility experiments. Med Image Comput Comput Assist Interv. 2011;14(Pt 1):33–40.
Conway BR. Recent patents on ocular drug delivery systems. Recent Pat Drug Deliv Formul. 2008;2(1):1–8.
Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging. 2010;27(2):117–34.
Jo DH, Kim JH, Lee TG, Kim JH. Nanoparticles in the treatment of angiogenesis-related blindness. J Ocul Pharmacol Ther. 2013;29(2):135–42.
Del Pozo-Rodríguez A, Delgado D, Gascón AR, Solinís MÁ. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther. 2013;29(3):173–88.
Kushwaha SK, Saxena P, Rai A. Stimuli sensitive hydrogels for ophthalmic drug delivery: a review. Int J Pharm Investig. 2012;2(2):54–60.
Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9–24.
Lam BL, Feuer WJ, Abukhalil F, Porciatti V, Hauswirth WW, Guy J. Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1. Arch Ophthalmol. 2010;128(9):1129–35.
Wert KJ, Davis RJ, Sancho-Pelluz J, Nishina PM, Tsang SH. Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet. 2013;22(3):558–67.
Biotech A. The Avalanche approach: how it works [Internet]. Avalanchebiotech. 2012 [cited 4 Apr 2013]. Available from: http://www.avalanchebiotech.com/how-it-works.php.
Rossmiller B, Mao H, Lewin AS. Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Mol Vis. 2012;18(February):2479–96.
Fujii Y, Kachi S, Ito A, Kawasumi T, Honda H, Terasaki H. Transfer of gene to human retinal pigment epithelial cells using magnetite cationic liposomes. Br J Ophthalmol. 2010;94(8):1074–7.
Lavinsky D, Chalberg TW, Mandel Y, Huie P, Dalal R, Marmor M, et al. Modulation of transgene expression in retinal gene therapy by selective laser treatment. Invest Ophthalmol Vis Sci. 2013;54(3):1873–80.
Hynes SR, Lavik EB. A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):763–78.
Schwartz SD, Hubschman J-P, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713–20. Elsevier Ltd.
Stanzel BV, Liu Z, Brinken R, Braun N, Holz FG, Eter N. Subretinal delivery of ultrathin rigid-elastic cell carriers using a metallic shooter instrument and biodegradable hydrogel encapsulation. Invest Ophthalmol Vis Sci. 2012;53(1):490–500.
Yanai A, Häfeli UO, Metcalfe AL, Soema P, Addo L, Gregory-Evans CY, et al. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplant. 2012;21(6):1137–48.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Electronic Supplementary Material
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hubschman, JP., Shah, S.U., Voleti, V.B. (2014). V.B.3. The Future of Vitrectomy. In: Sebag, J. (eds) Vitreous. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1086-1_40
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1086-1_40
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1085-4
Online ISBN: 978-1-4939-1086-1
eBook Packages: MedicineMedicine (R0)